Eli Lilly Files Lawsuits Targeting Alleged Sales of Unapproved Retatrutide
Key Takeaways:
- Eli Lilly has filed 6 lawsuits against pharmacies, medical spas, and peptide sellers that it alleges are unlawfully marketing versions of its investigational obesity drug retatrutide before the product has received regulatory approval.
- The litigation comes amid heightened federal scrutiny of unapproved glucagon-like peptide-1 (GLP-1) products, with the US Food and Drug Administration (FDA) stating that retatrutide cannot lawfully be used in compounding under federal law.1
- The cases highlight expanding compliance risks for pharmacies, telehealth providers, medical spas, and online sellers that market investigational products directly to consumers.
Eli Lilly has filed 6 lawsuits against US businesses it alleges are unlawfully marketing and selling products purporting to contain retatrutide, escalating the manufacturer's efforts to address an unauthorized market for its investigational obesity therapy.2,3
The lawsuits target Aesthetic Envy Cosmetic Centers, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide. The defendants include businesses operating as pharmacies, medical spas, wellness providers, and peptide vendors.2,3
The litigation is notable because retatrutide has not been approved by the FDA for any indication. Unlike disputes involving compounded versions of approved GLP-1 therapies, the retatrutide cases involve an investigational product that remains in clinical development.
Retatrutide Remains an Investigational Therapy
Retatrutide is being evaluated in Phase 3 clinical trials for obesity, type 2 diabetes, and related conditions. Lilly has described the investigational therapy as a once-weekly molecule targeting the glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors.
Because retatrutide has not received FDA approval, products sold outside authorized clinical research or other legally permitted access pathways have not undergone FDA review for safety, effectiveness, or quality.
FDA has specifically addressed retatrutide in its guidance concerning unapproved GLP-1 products, stating that retatrutide and cagrilintide cannot be used in compounding under federal law. The agency further notes that neither is a component of an FDA-approved drug and neither has been found safe and effective for any condition.1
FDA has also warned companies involved in marketing unapproved retatrutide, including telehealth companies selling products directly to consumers, active pharmaceutical ingredient distributors supplying retatrutide to compounders, and outsourcing facilities repackaging the investigational product.1
Lawsuits Target Marketing of Products Purporting to Contain Retatrutide
Lilly alleges that the 6 defendants marketed products purporting to contain retatrutide for human use despite the investigational status of the drug.2,3
Some sellers of unapproved peptides have attempted to characterize their products as intended only for research. FDA, however, has separately warned companies about unapproved semaglutide, tirzepatide, and retatrutide products labeled “for research purposes” or “not for human consumption” when the products were nevertheless sold directly to consumers with instructions indicating human use.1 That distinction is significant for pharmacies, medical spas, wellness clinics, and online peptide sellers.
Labeling a product as intended for research does not necessarily insulate a seller from regulatory scrutiny when surrounding marketing, dosing instructions, or other evidence demonstrates that the product is being offered for human use.
Lilly has also reportedly referred more than 200 individuals and entities to FDA, the Department of Justice, state attorneys general, law enforcement agencies, and professional licensing boards in connection with suspected unauthorized sales.2
FDA Intensifies Oversight of Unapproved GLP-1 Products
The litigation comes amid a broader federal effort to address the rapidly expanding market for unapproved GLP-1 products.
FDA has emphasized that compounded drugs do not undergo the agency's premarket review for safety, effectiveness, or quality. Although federal law permits compounding under specified circumstances, those exemptions are subject to statutory conditions and do not provide a general pathway for businesses to manufacture or market copies of investigational drugs.1
Retatrutide presents an especially clear regulatory distinction. Because it remains investigational, FDA has expressly stated that the compound cannot be used in compounding under federal law.1
The agency has also taken steps to address questionable GLP-1 products entering the U.S. supply chain, including import controls directed at active pharmaceutical ingredients with potential quality concerns.1
Enforcement Extends Beyond Manufacturers and Pharmacies
Lilly's response illustrates how enforcement surrounding unapproved obesity products may extend beyond traditional pharmaceutical manufacturers and pharmacies.
The company has called on social media companies, e-commerce platforms, payment processors, credit card companies, shipping providers, and government regulators to take additional action against sellers of products purporting to contain retatrutide.2
That approach reflects the increasingly digital nature of the market for unapproved weight-loss products. Consumers may encounter these products through social media advertising, telehealth platforms, medical spas, wellness businesses, or websites selling peptides directly to consumers.
For businesses operating in these channels, regulatory exposure may therefore extend beyond traditional pharmacy law to include federal drug requirements, advertising and marketing restrictions, state professional licensing requirements, and potentially civil litigation from pharmaceutical manufacturers.
Compliance Implications for Pharmacies and Digital Health Companies
The retatrutide litigation provides an important distinction for stakeholders navigating the rapidly evolving GLP-1 market: the existence of a developing or commercially attractive drug candidate does not create a lawful pathway to compound or sell versions of that investigational product.
Pharmacies, medical spas, telehealth companies, and peptide suppliers should evaluate not only how a product is labeled but also its regulatory status, sourcing, promotional claims, intended use, and whether federal law permits the substance to be used in compounding.
FDA's position on retatrutide also suggests that enforcement surrounding unapproved GLP-1 products is likely to remain focused on the entire distribution chain, including businesses supplying active pharmaceutical ingredients and entities marketing purported research products for consumer use.1
For pharmaceutical manufacturers, Lilly's lawsuits demonstrate another potential enforcement strategy: using private litigation alongside referrals to federal and state authorities to challenge unauthorized markets before an investigational therapy reaches commercial approval.
As retatrutide advances toward potential regulatory review, the lawsuits could provide an important test of how manufacturers, regulators, and courts address unauthorized versions of high-demand therapies that enter the consumer market before the underlying drug has been approved.
References
- US Food and Drug Administration. FDA's Concerns With Unapproved GLP-1 Drugs Used for Weight Loss. Updated June 15, 2026. Accessed August 12, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide. CNBC. Published August 12, 2026. Accessed August 12, 2026. https://www.cnbc.com/2026/08/12/lilly-lawsuits-obesity-drug-retatrutide.html
- Hamilton K. Eli Lilly Sues Sellers of Black Market Weight-Loss Drugs. WSJ. Published August 12, 2026. Accessed August 12, 2026. https://www.wsj.com/health/pharma/eli-lilly-sues-sellers-of-black-market-weight-loss-drugs-33c8f107
